AlphAIAlphAI — Financial news for AI agents
tradingview.comJUL 311 min read$MED

MED Q2'26 Earnings: EPS estimate is (0.65) USD

Medifast Inc. (MED) is scheduled to report Q2 2026 earnings on Aug. 3 after the market closes, with results expected at 4:05 PM ET. The consensus estimates call for revenue of $72.70 million and EPS of -$0.65 for the quarter, according to the article.

Original reporting
tradingview.com
Published Jul 31, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MED Q2'26 Earnings: EPS estimate is (0.65) USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$MEDNeutralMed
01

Why it matters

Traders can use the consensus revenue ($72.70M) and EPS (-$0.65) to frame expectations and manage event risk into the after-hours release.

02

Market read

The article is a scheduled earnings preview with consensus estimates, useful for event-risk positioning ahead of the print.

03

What to watch

Actual results could hinge on margin and subscriber retention trends, which are not discussed in the article, so consensus alone may not capture the key drivers.

Relevance 5/10Novelty 5/10Timing: ahead of Aug 03 after-hours earnings release

Background

MEDIFAST (MED) is set to announce Q2'26 earnings on Aug 03 after the market closes.

Company-level read

Ticker impact

$MEDNeutralLow confidence
Context

MEDIFAST is scheduled to report Q2'26 results Aug 03 after the close, with consensus revenue of $72.70M and EPS of -$0.65.

Expected impact

Likely volatility around the Aug 03 after-hours earnings release versus the -$0.65 EPS and $72.70M revenue expectations.

Evidence & confidence

The article provides only the scheduled earnings date and consensus estimates, with no new guidance, results, or surprises disclosed yet.

Market effects

Sector

Limited spillover; this is company-specific pre-earnings positioning for a diet/weight-management retailer.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the company has a history of beating or guiding conservatively, the negative EPS consensus may already be priced in, reducing incremental downside risk.

Key entities

  • public_company
    MED

    MEDIFAST Inc., scheduled to report Q2'26 results on Aug 03 after the close.

Read at source← All news

Related articles

AUG 4
$MEDHighAI 9/10

Why Medifast (MED) Stock Is Trading Up Today

Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.

financialcontent.com4 min
AUG 3
$MEDMed

Medifast Announces Second Quarter 2026 Financial Results

MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Second Quarter 2026 Financial Results August 3, 2026 BALTIMORE – ( BUSINESS WIRE ) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter

SEC EDGAR 8-K6 min
OCT 8
$LEVIHighAI 8/10

Levi Strauss Q3 Income Drops

Levi Strauss (LEVI) reported Q3 net income of $168.6M ($0.43 EPS), down from $218.1M ($0.55 EPS) last year. Adjusted earnings were $188.9M ($0.48 EPS). Revenue rose 4.3% to $1.609B. Full-year EPS guidance is $1.54-$1.56, adjusted for foreign exchange.

rttnews.com2 min
OCT 8
$STZMed

STZ SWOT Analysis: Financial Resilience Amidst Market Challenges

Constellation Brands Inc (STZ) reported a net income of $1.22 billion for the first half of 2026, with net sales reaching $5.07 billion. The company's GF Value suggests a 34% undervaluation. Strengths include a strong brand portfolio and operational efficiency, while weaknesses involve debt management and market reliance. Opportunities lie in premiumization, DTC expansion, and international growth, with threats from economic uncertainty and competition.

gurufocus.com2 min